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Black men in England have three times the age-adjusted incidence of diagnosed prostate cancer as compared with their White
counterparts. This population-based retrospective cohort study is the first UK-based investigation of whether access to diagnostic
services underlies the association between race and prostate cancer. Prostate cancer was ascertained using multiple sources including
hospital records. Race and factors that may influence prostate cancer diagnosis were assessed by questionnaire and hospital records
review. We found that Black men were diagnosed an average of 5.1 years younger as compared with White men (Po0.001). Men of
both races were comparable in their knowledge of prostate cancer, in the delays reported before presentation, and in their
experience of co-morbidity and symptoms. Black men were more likely to be referred for diagnostic investigation by a hospital
department (P¼0.013), although general practitioners referred the large majority of men. Prostate-specific antigen levels were
comparable at diagnosis, although Black men had higher levels when compared with same-age White men (Po0.001). In conclusion,
we found no evidence of Black men having poorer access to diagnostic services. Differences in the run-up to diagnosis are modest
and seem insufficient to explain the higher rate of prostate cancer diagnosis in Black men.
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Radical treatment can cure localised prostate cancer, but can lead
to serious side effects, and many untreated men do not develop
advanced disease (Albertsen et al, 2005). Risk factors and
prognostic factors are needed to identify those men with an
increased chance of developing cancer and of seeing that cancer
progress, as these men have a more favourable balance of risks and
benefits when undergoing screening tests and radical treatment.
Black race is one of very few factors supported by convincing
evidence (Gronberg, 2003). Surveillance, Epidemiology, and End
Results (SEER) data from the United States indicate that Black men
are 2.4 times more likely to die of prostate cancer than White men
of the same age (US Cancer Statistics Working Group, 2005). In
England, where prostate-specific antigen (PSA)-based screening is
uncommon, the PRostate Cancer in Ethnic SubgroupS (PROCESS)
study has demonstrated Black men to have 3.1 times the incidence
of prostate cancer as compared with their same-age White
counterparts (Ben-Shlomo et al, 2008). Black men also have a
poorer prognosis than similar age White men. A meta-analysis of
US data found the disease-specific case-fatality rate to be 29%
higher (Evans et al, 2008).
The higher rate of prostate cancer in Black men may arise from a
genuinely higher incidence, or alternatively there may be an equal
incidence of prostate cancer but a greater likelihood of diagnosis
among Black men. US studies suggest that Black men have worse
access to health care generally (Institute of Medicine, 2001), and
may have poorer access to PSA testing in particular (Freedland and
Isaacs, 2005), although a recent study has found Black men aged
40–49 years to be subject to a higher rate of testing (Ross et al,
2008). If Black men follow a different pathway to diagnosis
compared with White men, the relative incidence of prostate
cancer in US Black men may be obscured, making the role of
disease biology difficult to investigate. As the UK National Health
Service has an ethos of health-care equity (Whitehead, 1994), it is
possible that differences in the diagnostic pathways followed by
Black men and White men are avoided, in which case the higher
incidence of prostate cancer in Black men in the UK PROCESS
cohort could be more confidently attributed to a biological
mechanism. Consequently our objective, in this study of the
PROCESS cohort, is the first UK-based investigation of the
pathways to prostate cancer diagnosis followed by Black men
and White men in terms of demographic measures, knowledge
concerning prostate cancer, time from symptoms to presentation
and the reasons for delayed presentation, symptoms at presenta-
tion, referral pathways to diagnosis, and PSA level at diagnosis.
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sMATERIALS AND METHODS
PROCESS, a population-based retrospective cohort study, has
been described earlier (Ben-Shlomo et al, 2008). Males resident in
four study areas (North Bristol, South West London, South
East London, and North East London) were observed during
1995–1999 (Bristol) or 1997–2001 (London). Cases of prostate
cancer were ascertained from the following sequence of
sources: (a) pathology databases and (North West London only)
a urology department database, (b) hospital discharge diagnosis
files, (c) PSA records 410ngml
 1, and (d) Cancer Registry
(Bristol only). Where there was uncertainty, a panel of at least four
urologists classified a case vignette as a ‘clinical’ (non-histological
proven) case of prostate cancer, or excluded it due to a lack of
evidence.
Men known to be alive were asked to complete a questionnaire
including the 2001 census questions on ethnicity, with the next
of kin being contacted if the man had died more than 6 months
ago. Questionnaire information determined ethnicity for 37%
of Black men and 45% of White men. If a man’s ethnicity remained
undetermined, we referred in turn to hospital records (62% of
Black men, 50% of White men) and place of birth recorded
on the death certificate (1% of Black men, 5% White men).
Consultants recalled ethnicity for six men without other
information.
The questionnaire also assessed demographic information,
knowledge of prostate cancer, and delays in presenting with
symptoms. If the questionnaire was not completed, occupation
would be obtained from hospital records or the death certificate.
Occupations were classified as manual or non-manual according to
the Registrar General’s scheme (see http://www.statistics.gov.uk/).
Postcodes were linked to 1998 electoral wards (http://www.
edina.ac.uk/), then to the Index of Multiple Deprivation (IMD)
score for the year 2000 (http://www.neighbourhood.statistics.
gov.uk/). There are six domains (income; employment; health
deprivation and disability; education, skills and training; housing;
and geographical access to services) that determine the index score
for an area, higher scores indicating greater deprivation.
Trained research nurses reviewed hospital records using a
standard proforma (copies available from the authors), extracting
information on delays in presentation, the presence of co-morbid
illnesses contributing to the Charlson Index (Charlson et al, 1987),
symptoms at presentation, diagnosis in the absence of symptoms,
and referral pathways. To calculate the Charlson index for a man,
each of his co-morbid conditions was assigned a weight (e.g.,
1¼myocardial infarct, 2¼leukaemia, 3¼moderate or severe liver
disease, and 6¼AIDS) and the weights were added together
(Charlson et al, 1987). Although three centres completed reviews
for more than 85% of cases, time constraints restricted attention to
a sample of cases (70% of Black men and 42% of White men) at the
North East London centre. In addition, an attempt was made to
retrieve a measurement of each man’s PSA level from around the
time of diagnosis and prior to any treatment.
The South West Multi-Centre Research Ethics Committee
approved the PROCESS study.
Statistical analysis
Multivariable regression models estimated the associations be-
tween race and binary factors (logistic regression), unordered
categorical factors (multinomial regression), and ordered catego-
rical factors (ordered logistic regression) (Kirkwood and Sterne,
2003). Analyses were centre and age adjusted by including each of
these covariates in regression models as four dummy variables,
distinguishing the five study centres and five age categories. CI
denotes confidence interval, and P-values are two-tailed through-
out. Analyses were undertaken using Stata version 10 (StataCorp,
TX, USA, 2007).
RESULTS
Reviews of hospital records were available for 87% (474 out of 547)
of Black men and 75% (993 out of 1319) of White men;
questionnaire data for 38% (210) of Black men and 46% (601) of
White men. A greater proportion of Black men had completed the
questionnaire themselves (193, 92%) as compared with the White
men (463, 77%).
Black men presented at a younger age (mean: 67.9 years, s.d.: 7.3
years, n¼547) compared with White men (mean: 73.3 years, s.d.:
8.8 years, n¼1319), resulting in a centre-adjusted difference of 5.1
years (95% CI: 4.2–5.9 years, Po0.001). Black men lived in slightly
poorer neighbourhoods (mean IMD score: 44.6, s.d.: 14.4, n¼546)
compared with White men (mean IMD score: 41.7, s.d.: 17.0,
n¼1311), an age- and centre-adjusted difference of 1.45 (95% CI:
0.34–2.56, P¼0.010). More Black men (81%; 333 out of 413) than
White men (67%; 739 out of 1110) were in manual occupations
(Po0.001 age- and centre-adjusted).
The questionnaire assessed men’s knowledge of prostate cancer,
the responses in Table 1 being taken from those questionnaires
completed by the men themselves (i.e., excluding questionnaires
completed by next of kin). More White men correctly identified
ageing as an important cause of prostate cancer (Po0.001),
whereas just under half of both Black men and White men
correctly identified family history as an important cause. About
two-thirds of both Black men and White men correctly omitted
smoking from their list of risk factors. Several dietary components
are suspected risk factors for prostate cancer, and thus with some
justification around a one-third of both Black men and White men
identified bad diet as a risk factor. With similar justification, a
small number of men identified obesity as a risk factor, with strong
evidence that White men were more likely to select this factor
(P¼0.002). Black men were more likely to identify chemical
exposure (P¼0.026) and infection (P¼0.041), although convin-
cing evidence is yet to result from studies of these factors (Van
Maele-Fabry and Willems, 2003; Wagenlehner et al, 2007). Few
men volunteered other causes, notably race, which was missing
from the list provided. Further into the questionnaire men were
asked whether there was a difference in prostate cancer risk
between Black men and White men and if so which men were at
higher risk. Black men were less likely to take the ‘do not know’
option allowed for this question, and were more likely to know that
Black men are at higher risk (Po0.001; Table 1).
In 1997, there were 54 new cases of prostate cancer for every
10000 men aged 65 or over in the United Kingdom (www.cancer.
org.uk), Black men and White men being equally prone to
overestimate this figure (Table 1). More Black men correctly stated
lung cancer to be more or equally common to prostate cancer
(P¼0.033), whereas more White men were correct in stating that
testicular cancer was less common than prostate cancer (Po0.001;
male cancer incidences per 100000 person years in 1997 were 70
for prostate cancer, 77 for lung cancer; and 6 for testicular cancer).
Information on any delay between the appearance of symptoms
and first presentation to a doctor was collected from hospital
records and through an item in the questionnaire. There was 84%
agreement for the 91 men with information from both sources, and
as the questionnaire data and hospital records data supported
identical conclusions, only the former are presented (Table 2).
There was no convincing evidence of Black men delaying their
presentation more than White men with more than half of all men
seeking attention within 3 months of symptoms developing. More
than 95% of all men were able to provide at least one reason for
their delayed presentation, with Black men more likely to report
each of the reasons in Table 2. Once differences in age were
accounted for, Black men were more likely to be concerned that
their symptoms may be due to something serious (Po0.001), were
more embarrassed by their symptoms (P¼0.009), and were more
likely to dislike seeing their doctor in general (P¼0.030).
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co-morbid conditions (Table 3). Around 10% of men of both races
presented with symptoms suggestive of metastases, and around
two-thirds of all men presented with lower urinary tract symptoms
(LUTS), predominantly storage and voiding symptoms (Table 3).
There was weak evidence that Black men were more likely to be
Table 1 Knowledge of prostate cancer by race in PROCESS cohort members who completed the questionnaire themselves (i.e., excluding questionnaires
completed by next of kin)
Black men n (%) White men n (%) P-value
a
Three most important causes of prostate cancer?
Men responding with at least one cause 179 453
Ageing 119 (66) 368 (85) o0.001
Family history 81 (45) 160 (37) 0.051
Smoking 58 (32) 159 (37) 0.33
Bad diet 56 (31) 153 (35) 0.36
Infection 47 (26) 82 (19) 0.041
Chemical exposure 41 (23) 67 (15) 0.026
Occupation 24 (13) 51 (12) 0.56
Obesity 6 (3) 48 (11) 0.002
Where you live 13 (7) 19 (4) 0.14
Other 9 (5) 27 (6) 0.57
Comparing Black and White men
Black men have greater risk for prostate cancer 44 (23) 62 (13)
White men have greater risk for prostate cancer 0 (0) 13 (3)
No difference in risk 80 (42) 132 (29)
Do not know 65 (34) 242 (54) o0.001
10000 men over 65 years of age, how many new cases of prostate cancer in a 1-year period?
1 1 (1) 0 (0)
10 10 (6) 12 (3)
100 53 (29) 112 (25)
1000 59 (33) 173 (39)
1001+ 57 (32) 145 (33) 0.11
In men, lung cancer is
More common than prostate cancer 50 (28) 100 (23)
Equally common to prostate cancer 66 (37) 135 (31)
Less common than prostate cancer 61 (34) 200 (46) 0.033
Testicular cancer is
More common than prostate cancer 20 (13) 25 (6)
Equally common to prostate cancer 47 (30) 77 (19)
Less common than prostate cancer 90 (57) 313 (75) o0.001
Counts are the number of men providing the specified response.
aP-values are obtained using a Pearson’s w
2 test.
Table 2 Delay between start of symptoms and first presentation, and patient-reported reasons by race in PROCESS cohort members
Centre-adjusted Age and centre adjusted
Black men
n (%)
White men
n (%)
Odds ratio
(95% CI) P-value
Odds ratio
(95% CI) P-value
Delay seeking medical attention (n¼522)
Less than 1 month 50 (34) 126 (34)
1–3 months 35 (24) 98 (26)
4–6 months 28 (19) 51 (14)
7–12 months 24 (16) 52 (14)
1 or 2 years 5 (3) 27 (7)
More than 2 years 4 (3) 22 (6)
Odds ratio per category change 0.93 (0.66, 1.32) 0.69 0.82 (0.57, 1.19) 0.30
At least one reason given (n¼590) 164 426
Did not think symptoms were serious 79 (48) 169 (40) 1.38 (0.95, 2.02) 0.095 1.20 (0.80, 1.79) 0.37
Do not like seeing my own doctor in general 32 (20) 60 (14) 1.57 (0.95, 2.60) 0.076 1.81 (1.06, 3.10) 0.030
Was scared that it might be something serious 59 (36) 83 (19) 2.25 (1.48, 3.42) o0.001 2.55 (1.62, 4.00) o0.001
Found the symptoms an embarrassing problem 54 (33) 107 (25) 1.61 (1.06, 2.44) 0.024 1.81 (1.16, 2.81) 0.009
Data from questionnaire; 92 men reported not being able to remember the length of the delay, although most of these could provide a reason for the delay. Counts are the
number of men providing the specified response.
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(P¼0.052), although this association was attenuated after
accounting for the age difference.
Referrals to a specialist for diagnosis, an urologist in 97% of
cases, came from general practitioners, accident and emergency
departments, and other hospital departments. Age- and centre-
adjusted multinomial logistic regression analyses provided evi-
dence that the presence of symptoms (Po0.001) and race
(P¼0.013) were independently associated with the source of the
referral (Table 4). In particular, although general practitioners
Table 3 Co-morbidity, symptoms at diagnosis, and route to diagnosis in the absence of symptoms by race in PROCESS cohort members; information
from hospital records
Centre adjusted Age and centre adjusted
Black men
n (%)
White men
n (%)
Odds ratio
(95% CI) P-value
Odds ratio
(95% CI) P-value
Charlson co-morbidity score (n¼1296)
0 257 (61) 494 (57)
1 96 (23) 177 (20)
2+ 69 (16) 203 (23)
Odds ratio per category change 0.95 (0.75, 1.22) 0.71 1.21 (0.94, 1.57) 0.14
Hospital records review available (n¼1467) 474 993
Symptoms of metastasis? 52 (11) 111 (11) 1.13 (0.78, 1.64) 0.51 1.32 (0.89, 1.96) 0.17
LUTS? 301 (64) 671 (68) 0.95 (0.74, 1.20) 0.66 1.02 (0.79, 1.31) 0.87
Storage symptoms? 232 (49) 537 (54) 0.96 (0.76, 1.21) 0.71 1.01 (0.79, 1.29) 0.96
Voiding symptoms? 227 (48) 537 (54) 0.88 (0.70, 1.11) 0.29 0.91 (0.71, 1.15) 0.42
Acute urinary retention? 55 (12) 113 (11) 1.04 (0.72, 1.49) 0.85 1.40 (0.95, 2.07) 0.093
Haematuria? 34 (7) 104 (10) 0.67 (0.44, 1.01) 0.056 0.72 (0.47, 1.12) 0.15
Urinary tract infection? 35 (7) 62 (6) 1.19 (0.76, 1.85) 0.45 1.49 (0.92, 2.42) 0.10
Chronic urinary retention? 17 (4) 49 (5) 0.66 (0.37, 1.18) 0.17 0.83 (0.45, 1.53) 0.55
Diagnosed in the absence of symptoms
With a PSA test 77 (16) 110 (11) 1.38 (1.00, 1.92) 0.052 1.26 (0.89, 1.77) 0.19
With digital rectal exam 18 (4) 34 (3) 1.07 (0.58, 1.96) 0.83 1.07 (0.57, 2.04) 0.83
With TURP 13 (3) 33 (3) 1.19 (0.58, 2.46) 0.64 1.59 (0.73, 3.46) 0.25
LUTS¼lower urinary tract symptoms; PSA¼prostate-specific antigen; TURP¼trans-urethral resection of the prostate. Counts are the number of men with the specified
information in their hospital records.
Table 4 Pathways to diagnosis for Black and White men, with and without symptoms
Status at first appointment for diagnosis
Source of referral Outpatient (%) In-patient (%) Total
Symptomatic – Black men
General practitioner 214 (81) 7 (11) 221 (68)
Accident and emergency 9 (3) 25 (39) 34 (10)
Hospital team 25 (10) 32 (50) 57 (17)
Other 15 (6) 0 (0) 15 (5)
Total 263 (100) 64 (100) 327 (100)
Symptomatic – White men
General practitioner 485 (85) 39 (27) 524 (74)
Accident and emergency 10 (2) 43 (30) 53 (7)
Hospital team 38 (7) 58 (40) 96 (13)
Other 35 (6) 4 (3) 39 (5)
Total 568 (100) 144 (100) 712 (100)
No symptoms – Black men
General practitioner 65 (67) 2 (17) 67 (61)
Accident and emergency 2 (2) 3 (25) 5 (5)
Hospital team 18 (19) 6 (50) 24 (22)
Other 12 (12) 1 (8) 13 (12)
Total 97 (100) 12 (100) 109 (100)
No symptoms – White men
General practitioner 77 (65) 5 (12) 82 (51)
Accident and emergency 1 (1) 5 (12) 6 (4)
Hospital team 23 (19) 15 (37) 38 (24)
Other 18 (15) 16 (39) 34 (21)
Total 119 (100) 41 (100) 160 (100)
Data from hospital records. Counts are the number of men with the specified combination of information in their hospital records.
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men were more likely than White men to be referred by the
emergency department (odds ratio 1.66, 95% CI: 1.02–2.70) or
another hospital team (odds ratio 1.67, 95% CI: 1.17–2.39). An
age- and centre-adjusted logistic regression analysis, including
referral source, race, and symptoms as covariates, indicated that
referral source was associated with diagnosis as an inpatient
(Po0.001) but that symptoms at diagnosis were not (P¼0.25).
Evidence of Black men being less likely to be diagnosed as
inpatients was apparent in a centre-adjusted analysis (P¼0.011),
but the association was largely explained by the younger age of
the Black men (age- and centre-adjusted odds ratio¼0.75, 95% CI:
0.49–1.15; P¼0.19).
A pretreatment PSA level at diagnosis was available for
458 Black men and 921 White men. The level was 10ngml
 1 or
less for 121 (26%) Black men and 226 (25%) White men, was
more than 10ngml
 1 but no more than 20ngml
 1 for 79 (17%)
Black men and 199 (22%) White men, and was more than
20ngml
 1 but no more than 100ngml
 1 in 163 (36%) Black men
and 303 (33%) White men. A centre-adjusted comparison of these
PSA levels between Black men and White men provided no
convincing evidence of a difference (ordered logistic regression
odds ratio 1.14, 95% CI: 0.92–1.41, P¼0.23), but there was strong
evidence of higher levels in Black men when differences in age at
diagnosis were accounted for (odds ratio 1.59, 95% CI: 1.27–1.99,
Po0.001).
DISCUSSION
In this cohort of men in southern England, Black men were
diagnosed with prostate cancer at a younger age than White
men, lived in less affluent areas and were more likely to have
been in a manual occupation. Knowledge of prostate cancer was
comparable, with White men more likely to know of age as a
risk factor and Black men more likely to know of their own
higher risk of developing the disease. There was no evidence
of Black men or White men being more likely to delay presentation
with symptoms, although Black men reported more reasons
if they had delayed presentation. At diagnosis, Black men and
White men were equally likely to have co-morbidity, symptoms of
metastatic prostate cancer, and LUTS. There was weak evidence
that Black men were more likely to have had their PSA level
measured in the absence of symptoms, although this difference
appeared to be due to the younger age of the Black men at
diagnosis. Compared with White men of the same age, Black men
were more likely to have been referred for diagnosis by a hospital-
based team. At the time of diagnosis, Black men and White men
had comparable PSA levels, although evidence of higher levels in
Black men emerged when compared with their same-age White
counterparts.
Our finding that Black men are diagnosed 5 years earlier than
White men is in part explained by differences in the study
population age distributions of these two groups. This is not a
complete explanation as there is evidence of an interaction
between race and age in the PROCESS study cohort (Po0.001),
with the higher relative rates for Black men compared with White
men being more marked for the younger age groups (Ben-Shlomo
et al, 2008). This interaction was not found for the US-based
Health Professionals Follow-up Study (Giovannucci et al, 2007),
but analysis of US SEER data still finds Black men to be diagnosed
when an average of 3 years younger than White men (Karami et al,
2007), in the absence of marked racial differences in age
distribution in the United States.
It is possible that Black men are developing prostate cancer at
the same age on average as White men but are being diagnosed
earlier, this partially explaining the apparently higher incidence
rate in Black men. This explanation is unlikely for the following
reasons: (i) Black men were more likely to be in less affluent
socioeconomic positions, such positions being associated with
poorer access to health-care services (Nazroo, 1997); (ii) although
Black men are more likely than White men to know of their own
higher risk for prostate cancer, this knowledge was far from
widespread in the study population, as has been observed
elsewhere (Schulman et al, 2003); (iii) there was no evidence that
Black men sought medical attention earlier for their symptoms, in
line with data from the ‘National Survey of NHS patients: Cancer’
(Neal and Allgar, 2005); (iv) it is unlikely that Black men were
subject to a higher rate of incidental detection, as they were no
more likely to have co-morbidities or LUTS, and a higher chance
of having been referred for diagnostic investigation by a hospital
department is in the context of the large majority of all men having
been referred by their GP. There was weak evidence of more Black
men being diagnosed in the absence of symptoms following a PSA
test, but this is largely explained by higher rates of PSA testing in
younger men in the study population. In any case PSA levels, and
the prevalence of symptoms suggestive of metastases, are
comparable between Black men and White men, both these factors
suggesting diagnosis at a similar stage of the disease. Conse-
quently, the diagnosis of prostate cancer in Black men at an
earlier age may be due to a greater biological susceptibility to the
disease.
Our study is limited by its retrospective design, and the
consequent reliance on extracting data from routine medical
records and on the information recalled by men when com-
pleting the questionnaires. However, although the completeness
and accuracy of measurements derived from routine records
is of general concern, there is no reason to expect differences
in record keeping practice for Black patients and White patients
to introduce bias into our results. The detailed questionnaire
may have been off-putting for some men, and it may be that
those men who failed to return the questionnaire are more
likely to have difficulty accessing health-care services (Wolf
et al, 2006). Consequently measures derived from the
questionnaire should be interpreted with this possible bias in
mind.
In conclusion, differences in knowledge of prostate cancer, co-
morbidity, testing rates, presentation following the appearance of
symptoms, and referral pathways, are modest and seem insuffi-
cient to explain the higher rate of prostate cancer diagnosis in
Black men compared with their White counterparts. We found no
evidence that Black men had better or worse access to diagnostic
services, our data being consistent with a genuinely higher prostate
cancer incidence rate in Black men. Comparable PSA levels
between Black men and White men suggest that diagnosis occurs
at a similar disease stage; future studies of the PROCESS cohort
will ascertain whether clinical management and prognosis are also
comparable.
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